Repligen (NASDAQ:RGEN) Releases Earnings Results, Beats Expectations By $0.10 EPS

Repligen (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10, FiscalAI reports. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. During the same period last year, the business earned $0.39 EPS. The company’s revenue was up 14.8% on a year-over-year basis. Repligen updated its FY 2026 guidance to 1.970-2.050 EPS.

Here are the key takeaways from Repligen’s conference call:

• Repligen reported strong Q1 results with $194M revenue (15% reported, 11% organic), 160 bps adjusted operating margin expansion, and raised full?year adjusted EPS guidance to $1.97–$2.05.
• Management launched a Transformation Office to accelerate cost, manufacturing and IT/AI improvements, targeting at least 1 point of annualized margin benefit by end?2027 and advancing the path to 30% adjusted EBITDA by 2030 (with ~$5–6M of non?recurring charges).
• China and Asia Pacific momentum picked up meaningfully—China revenues nearly doubled in Q1 and the company signed an OEM partnership to expand local manufacturing and competitiveness beginning in 2027.
• Franchise strength was broad?based and higher?margin—analytics grew 50%+ (now guided to 20%+ for 2026), chromatography rose >25% (now guided >20%), and proteins delivered mid?teens growth with expectations of low double?digit growth for the year.
• Filtration/ATF growth was moderated for 2026 due to specific customer timing and a gene?therapy headwind; the divestiture of the loss?making Polymem business removes about $7M of FY revenue even as it improves margin outlook.

Repligen Trading Up 6.0%

RGEN stock traded up $7.13 on Tuesday, hitting $125.34. 1,126,330 shares of the company were exchanged, compared to its average volume of 870,602. Repligen has a twelve month low of $109.50 and a twelve month high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The business’s fifty day moving average is $121.56 and its two-hundred day moving average is $144.68. The stock has a market capitalization of $7.07 billion, a price-to-earnings ratio of 147.67, a price-to-earnings-growth ratio of 2.28 and a beta of 1.09.

Analyst Ratings Changes

A number of research firms have commented on RGEN. Roth Mkm initiated coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective on the stock. HC Wainwright boosted their price objective on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Wells Fargo & Company cut their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Canaccord Genuity Group cut their target price on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $170.25.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC acquired a new position in Repligen during the third quarter worth approximately $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen during the fourth quarter worth approximately $36,000. Itau Unibanco Holding S.A. increased its position in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in Repligen during the third quarter worth approximately $65,000. Finally, Wilmington Savings Fund Society FSB increased its position in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 495 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.